"As US funding falters, mRNA cancer vaccine pioneers face new hurdles" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

BIDMC scientists developed a trivalent mRNA TB vaccine that outperformed the old BCG shot in mice and is moving toward Phase 1 human trials.

Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

Dr. Sarah Boyd, an infectious disease specialist with Saint Luke's Health System, told KCUR that federal cuts to mRNA research and development could cause a setback in pandemic preparedness. Last week ...

Russia has announced that its experimental mRNA-based cancer vaccine, Enteromix, showed 100 per cent efficacy and safety in ...